vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Northwest Bancshares, Inc. (NWBI). Click either name above to swap in a different company.
Northwest Bancshares, Inc. is the larger business by last-quarter revenue ($175.1M vs $168.4M, roughly 1.0× Esperion Therapeutics, Inc.). Over the past eight quarters, Northwest Bancshares, Inc.'s revenue compounded faster (33.7% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Northwest Bank is a bank headquartered in Warren, Pennsylvania. It is the leading subsidiary of Northwest Bancshares, Inc., a bank holding company, and operates 151 branches in Pennsylvania, Western New York, Northeast Ohio, Appalachian Ohio, and Indiana.
ESPR vs NWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $175.1M |
| Net Profit | — | $50.5M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 28.9% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $175.1M | ||
| Q4 25 | $168.4M | $179.9M | ||
| Q3 25 | $87.3M | $168.2M | ||
| Q2 25 | $82.4M | $150.4M | ||
| Q1 25 | $65.0M | $156.2M | ||
| Q4 24 | $69.1M | $154.3M | ||
| Q3 24 | $51.6M | $139.1M | ||
| Q2 24 | $73.8M | $98.0M |
| Q1 26 | — | $50.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $3.2M | ||
| Q2 25 | $-12.7M | $33.7M | ||
| Q1 25 | $-40.5M | $43.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $33.6M | ||
| Q2 24 | $-61.9M | $4.7M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 32.6% | ||
| Q3 25 | -11.4% | 2.1% | ||
| Q2 25 | 8.6% | 29.3% | ||
| Q1 25 | -34.0% | 36.2% | ||
| Q4 24 | -6.4% | 27.5% | ||
| Q3 24 | -31.0% | 31.3% | ||
| Q2 24 | 3.5% | 6.1% |
| Q1 26 | — | 28.9% | ||
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 1.9% | ||
| Q2 25 | -15.4% | 22.4% | ||
| Q1 25 | -62.2% | 27.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 24.2% | ||
| Q2 24 | -83.9% | 4.8% |
| Q1 26 | — | $0.34 | ||
| Q4 25 | $0.32 | $0.30 | ||
| Q3 25 | $-0.16 | $0.02 | ||
| Q2 25 | $-0.06 | $0.26 | ||
| Q1 25 | $-0.21 | $0.34 | ||
| Q4 24 | $-0.14 | $0.26 | ||
| Q3 24 | $-0.15 | $0.26 | ||
| Q2 24 | $-0.33 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $286.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.9B |
| Total Assets | $465.9M | $16.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $286.7M | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $-302.0M | $1.9B | ||
| Q3 25 | $-451.4M | $1.9B | ||
| Q2 25 | $-433.5M | $1.6B | ||
| Q1 25 | $-426.2M | $1.6B | ||
| Q4 24 | $-388.7M | $1.6B | ||
| Q3 24 | $-370.2M | $1.6B | ||
| Q2 24 | $-344.2M | $1.6B |
| Q1 26 | — | $16.9B | ||
| Q4 25 | $465.9M | $16.8B | ||
| Q3 25 | $364.0M | $16.4B | ||
| Q2 25 | $347.1M | $14.5B | ||
| Q1 25 | $324.0M | $14.5B | ||
| Q4 24 | $343.8M | $14.4B | ||
| Q3 24 | $314.1M | $14.4B | ||
| Q2 24 | $352.3M | $14.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $153.4M | ||
| Q3 25 | $-4.3M | $41.9M | ||
| Q2 25 | $-31.4M | $-2.3M | ||
| Q1 25 | $-22.6M | $107.6M | ||
| Q4 24 | $-35.0M | $127.7M | ||
| Q3 24 | $-35.3M | $93.3M | ||
| Q2 24 | $-7.2M | $40.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $141.8M | ||
| Q3 25 | — | $38.3M | ||
| Q2 25 | — | $-6.0M | ||
| Q1 25 | — | $105.8M | ||
| Q4 24 | — | $125.4M | ||
| Q3 24 | $-35.5M | $93.2M | ||
| Q2 24 | $-7.3M | $37.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.8% | ||
| Q3 25 | — | 22.8% | ||
| Q2 25 | — | -4.0% | ||
| Q1 25 | — | 67.7% | ||
| Q4 24 | — | 81.3% | ||
| Q3 24 | -68.7% | 67.0% | ||
| Q2 24 | -9.9% | 37.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 6.5% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 1.5% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 3.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 13.24× | ||
| Q2 25 | — | -0.07× | ||
| Q1 25 | — | 2.48× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.77× | ||
| Q2 24 | — | 8.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NWBI
| Net Interest Income | $142.5M | 81% |
| Noninterest Income | $32.6M | 19% |
